地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771997407
传真:17754422825
邮箱:sales@amyjet.com

Dendritics公司主要关注人类树突状细胞,希望找到能够促使CD34+造血前体细胞转化为树突状细胞(在GM-CSF和TNF-alpha存在的情况下)的细胞因子。在1992-2005年间,大量的研究使得研究者对人类树突状细胞的产生、细胞通路、C-type凝集素受体的功能及Toll-like受体的活性有了更深的理解。
DENDRITICS was started in 2005 by former members of SCHERING PLOUGH Laboratory for Immunological Research (LIR) in Dardilly, France. From their long experience at LIR, the team members of DENDRITICS have gathered complementary scientific and technological knowledge in different areas of immunology. The initial focus of LIR was in the biology of B lymphocytes, elaboration of human monoclonal antibodies, and in cytokine discovery (IL-3, IL-4, IL-7, IL-10, IL-17, GM-CSF) together with our colleagues of DNAX Research Institute in Palo Alto, California.
Our interest in cytokines led to the finding that human dendritic cells (DCs) could be generated in vitro from CD34+ hematopoietic progenitors cultured in the presence of GM-CSF and TNF-alpha.
The period from 1992 to 2005 saw the specialization of LIR in DC biology and was fuelled by a large-scale effort to discover and study the function of genes specifically expressed by these cells. This program led to a number of findings that contributed in particular to understanding the heterogeneity of DCs, the pathways regulating DC migration, the function of C-type lectin receptors in DCs and the activity of Toll-like receptors in DCs. Many novel genes were discovered through screening of cDNA libraries or through monoclonal antibodies raised against DCs.
<<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://biomatik.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Dendritics"> Dendritics
艾美捷科技代理IHC World品牌。
IHC World公司的产品与服务包括:
(1)抗体:提供多种一抗和二抗,适用于不同靶标和物种。
(2)试剂盒:包括染色试剂盒、检测试剂盒等,简化实验流程。
(3)仪器与设备:提供染色机、切片机等实验室设备。
(4)耗材:如玻片、盖玻片、封片剂等。
(5)定制服务:根据客户需求提供定制抗体开发和优化服务。
IHC World公司的产品应用领域:
(1)癌症研究:用于肿瘤标志物检测和癌症分型。
(2)神经科学:研究神经系统疾病和神经标记物。
(3)传染病研究:检测病原体及其在组织中的分布。
(4)药物开发:评估药物对组织的影响。
" data-original="http://biomatik.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理IHC World品牌"> 艾美捷科技代理IHC World品牌
<艾美捷科技代理GenoSensor Corporation品牌全系列产品
GenoSensor Corporation是一家基因组技术公司,专注于为从事基因组研究和/或需要基因组解决方案的生命科学领域客户提供产品和服务。公司产品线包括:微RNA芯片、PCR/实时定量PCR(QPCR)试剂盒、基因组改变分析工具,DNA提取试剂盒以及临床应用的专用试剂盒及试剂。

▎GenoSensor Corporation产品线
● MicroRNA Expression Profiling
MicroRNA是约21个核苷酸(NT)的非编码小RNA,参与转录后调控,并在多种细胞和生物体中表达。GenoExplorer™ microRNA生物芯片和检测方法为研究microRNA表达及其谱分析提供了支持。microRNA芯片包括人、小鼠、大鼠、果蝇、秀丽隐杆线虫、拟南芥以及其他物种的芯片,GenoExplorer™微阵列以高重复性、高信噪比和高灵敏度为标志,展现出高品质性能。
| 货号 | 品名 | 产品描述 | 规格 |
| 1101C | GenoExplorer™ microRNA kit - human 4 | GenoExplorer™ microRNA chips, labeling reagent, hybridization buffer and washing solutions | 4 reactions |
| 1102C | GenoExplorer™ microRNA kit - human 20 | 20 reactions | |
| 1111C | GenoExplorer™ microRNA kit - mouse/rat 4 | 4 reactions | |
| 1112C | GenoExplorer™ microRNA kit - mouse/rat 20 | 20 reactions | |
| 1121C | GenoExplorer™ microRNA kit - C. elegans 4 | 4 reactions | |
| 1122C | GenoExplorer™ microRNA kit - C. elegans 20 | 20 reactions | |
| 1131C | GenoExplorer™ microRNA kit - Drosophila melanogaster 4 | 4 reactions | |
| 1132C | GenoExplorer™ microRNA kit - Drosophila melanogaster 20 | 20 reactions | |
| 1141C | GenoExplorer™ microRNA kit - Arabidopsis thaliana 4 | 4 reactions | |
| 1142C | GenoExplorer™ microRNA kit - Arabidopsis thaliana 20 | 20 reactions | |
| 1199 | GenoExplorer™ microRNA for other species | - | |
| 1301 | GenoExplorer™ microRNA array labeling kit | GenoExplorer™microRNA labeling kit | 20 reactions |
| 1302 | GenoExplorer™microRNA labeling kit is ONLY available with purchase of full kits | GenoExplorer™microRNA labeling kit is ONLY available with purchase of full kits | 4 reactions |
| 1201C | GenoExplorer™ microRNA cihp - human 4 | GenoExplorer™ microRNA chips and 2x hybridization buffer | 4 chips (4 arrays) |
| 1202C | GenoExplorer™ microRNA cihp - human 20 | 20 chips (20 arrays) | |
| 1211C | GenoExplorer™ microRNA cihp - mouse/rat 4 | 4 chips (4 arrays) | |
| 1212C | GenoExplorer™ microRNA chip - mouse/rat 20 | 20 chips (20 arrays) | |
| 1221C | GenoExplorer™ microRNA chip - C. elegans 4 | 4 chips (4 arrays) | |
| 1222C | GenoExplorer™ microRNA chip - C. elegans 20 | 20 chips (20 arrays) | |
| 1231C | GenoExplorer™ microRNA chip - Drosophila melanogaster 4 | 4 chips (4 arrays) | |
| 1232C | GenoExplorer™ microRNA chip - Drosophila melanogaster 20 | 20 chips (20 arrays) | |
| 1241C | GenoExplorer™ microRNA chip - Arabidopsis thaliana 4 | 4 chips (4 arrays) | |
| 1242C | GenoExplorer™ microRNA chip - Arabidopsis thaliana 20 | 20 chips (20 arrays) | |
| 1299 | GenoExplorer™ microRNA for other species | - | |
| 1401C | GenoExplorer™ microRNA probe set - human | 1 complete GenoExplorer™ microRNA probe set for human in 384-well plates | 500 pmol |
| 1411C | GenoExplorer™ microRNA probe set - mouse/rat | 1 complete GenoExplorer™ microRNA probe set for mouse in 384-well plates | 500 pmol |
| 1421C | GenoExplorer™ microRNA probe set - C. elegans | 1 complete GenoExplorer™ microRNA probe set for C. elegans in a 384-well plate | 500 pmol |
| 1431C | GenoExplorer™ microRNA probe set - Drosophila melanogaster | 1 complete GenoExplorer™ microRNA probe set for Drosophila melanogaster in a 384-well plate | 500 pmol |
| 1441C | GenoExplorer™ microRNA probe set - Arabidopsis thaliana | 1 complete GenoExplorer™ microRNA probe set for Arabidopsis thaliana in a 384-well plate | 500 pmol |
| 1499 | GenoExplorer™ microRNA for other species | 1 complete GenoExplorer™ microRNA probe set in 384-well plates | - |
| 1501 | 2x Hybridization buffer | 2x hybridization buffer with optimized salt and formamide | 5 x 1ml |
| 1502 | 2x printing buffer | 2x phosphate printing buffer pH 8.3 | 100 ml |
| 1503 | Blocking buffer | Blocking buffer (or Buffer S for GenoExplorer array kit) | 5 x 1ml |
| 1504 | Washing buffers | Washing buffer I and II (concentrated) | 120 and 50 ml |
● MicroRNA qRT-PCR Analysis
GenoExplorer™microRNA qRT-PCR试剂盒提供了一个简单且高灵敏度的工具,用于定量检测特定的miRNA。该试剂盒可测量miRNA的成熟形式或前体形式,或者同时测量两种形式。
<| 货号 | 品名 | 产品描述 | 规格 |
| 2001 | GenoExplorer™ miRNA qRT-PCR Kit-100 | Provides complete set for miRNA quantitation including first-strand cDNA synthesis and SYBR® Green I qPCR reagent mix. (primers not included, see Cat# 2003 and 2004) | 100 reactions |
| 2002-10 | GenoExplorer™ miRNA First-Strand cDNA Core Kit-10 | Provides necessary core components to generate miRNA first-strand cDNA for miRNA expression quantitation. | 10 reactions |
| 2002-50 | GenoExplorer™ miRNA First-Strand cDNA Core Kit-50 | 50 reactions | |
| 2003 | GenoExplorer™ miRNA qPCR Primer Sets | Provides specific primer pair for miRNA quantitation analysis (3µM each). Suggest to combine with GenoExplorer™ miRNA qRT-PCR Kit-100 (Cat# 2001) and reference primer sets (Cat# 2004). Refer miRBase for available genes and primers. | 100 µl |
| 2004 | GenoExplorer™ miRNA qPCR Reference Primer Sets | Reference primer as an internal control reference (3µM each). Suggest to combine with GenoExplorer™ miRNA qRT-PCR Kit-100 (Cat# 2001) and GenoExplorer™ miRNA qPCR Primer Sets (Cat# 2003).Selection of human-U6, human-U44, human-5SrRNA; mouse-U6, mouse-5SrRNA; rat-U6, rat-5SrRNA; Drosophila-U6 and 5SrRNA | 100 µl |
| 2005 | GenoExplorer™ 2X qPCR Mix | 2X SYBR® Green I qPCR mix, specifically for miRNA and small RNA amplification and quantification, containing all PCR reagents and polymerase | 750 µl |
● Gene Expression Profiling
GenoExplorer™ 基因表达谱分析生物芯片包括:针对选定基因及其可变剪接异构体的定制微阵列,涵盖人、小鼠、大鼠及其他物种的完整基因文库,以及用于表达研究的基因子集。
| 品名 | 产品描述 |
| GenoExplorer™ Human Genome Chips | Microarray contains 29K human microRNA sequences |
| GenoExplorer™ Human Functional Genomics Chips | Microarrays include the subsets of functional genes and ESTs, such as signal transduction, liver enzymes, etc. |
| Custom Chips | We will help you design your custom chips for the genes that you are interested in. |
● COVID-19检测试剂盒
GenoSensor开发了一种高灵敏度检测方法,利用实时逆转录聚合酶链反应(RT-PCR) 直接检测病毒基因组(RNA),具有操作简便和可实时检测得特点。
| 货号 | 品名 | 产品描述 | 规格 |
| 2702-22 | GS™ COVID-19 Real-Time PCR Kit - 30 | Provide all-in-one master mix including cDNA synthesis, PCR mix, primers and probe of each gene. | 22 samples |
| 2702-94 | GS™ COVID-19 Real-Time PCR Kit - 126 | 94 samples |
● QS™ DNA 提取试剂盒
QS™ DNA 提取试剂盒包含的试剂能够裂解细胞、使蛋白质变性,并保护核酸免受核酸酶和氧化作用的降解。该方法极其快速且简单,只需两步操作,即可从多种类型的组织和细胞中提取 DNA,提取的可直接用于 PCR 和测序分析,无需纯化步骤。
| 货号 | 品名 | 产品描述 | 规格 |
| QS8001 | QS™ DNA Extraction kit | Solution A (Lysis)100ml and Solution B (Balance) | 10ml |
▎GenoSensor Corporation提供的服务
● 基因组改变分析:包括多态性基因分型(如SNPs和STRs)、基因组结构分析、基因扩增与缺失分析以及基因组重排分析。
● 定制微阵列:根据提供探针化学物质,构建经过质量控制的阵列。临床应用:专门为癌症和心血管疾病开发和销售基因产品。
● 靶标制备:例如从组织、培养物和微生物中分离和纯化基因组DNA、质粒DNA和RNA。
● 靶基因扩增、定量和标记:提供基因扩增、产物定量和靶标标记服务。
● 测序:基因测序使用ABI测序系统进行。

艾美捷科技代理T&T scientific品牌。
T&T Scientific 是一家专注于药物纳米医药制剂研发和制造的技术与服务公司。T&T Scientific 拥有三大核心部门:1) 合同研究、开发和 cGMP 制造;2) 制造平台全覆盖技术(供内部使用或销售);3) 脂质纳米颗粒制剂的发现、优化和技术开发。T&T Scientific 的质量体系由质量团队和电子质量系统(Qualio)管理。T&T Scientific 的质量部门确保药品质量以及技术转移过程的质量控制。T&T Scientific提供 PEG 化磷脂、常规磷脂、脂质体挤出器。
" data-original="http://biomatik.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理T&T scientific品牌"> 艾美捷科技代理T&T scientific品牌

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://biomatik.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
<艾美捷科技代理visikol品牌全系列产品
Visikol是一家合同研究服务公司,专门从事先进的细胞培养检测和先进的组织成像。自 2016 年成立以来,Visikol开发了一系列组织成像和细胞培养工具,已被所有 20 家前 20 家制药公司和 1,000 多个研究实验室使用。Visikol专注于通过为制药和生物技术公司提供先进的成像和细胞培养工具来加速药物发现和开发过程。这些工具确保药物在发现过程中更快地失败,并且研究人员可以回答更复杂的研究问题,为他们的项目提供信息。Visikol公司的产品线包括:Visikol HISTO组织透明化、Visikol HISTO-M 用于 3D 细胞模型、Visikol® 用于植物生物学™、HUREL产品、辅料。

▍visikol公司产品线
● Visikol HISTO组织透明化:Visikol HISTO通过将组织清除与荧光蛋白和/或免疫荧光相结合,使研究人员能够轻松地以3D方式可视化生物组织。具有以下优势:
1)无损技术:保持组织的完整性和自然结构。
2)快速高效:加速了组织清除和成像的过程。
3)易于使用:简化了复杂的组织清除步骤,使更多研究人员能够轻松掌握。
● Visikol HISTO-M 用于3D细胞培养模型:3D细胞培养模型因其能够更好地模拟体内环境而在药物发现领域得到广泛应用。具有以下功能与特点:
1)组织透明化:Visikol HISTO-M是一种专为3D细胞培养模型和基于板的高通量处理而设计的组织透明化技术。
2)成像与分析:当与荧光标记(如荧光蛋白、免疫荧光、化学染料)和高内涵共聚焦显微镜配合使用时,Visikol HISTO-M可以实现完整的3D细胞培养模型表征和更准确的药物筛选。
● Visikol for Plant Biology:旨在直接替代Hertwig的解决方案,用于使植物组织透明以供显微镜检查。使用100mL Visikol,可以清除多达500张显微镜载玻片上的植物组织。具有以下优势:
1)高效便捷:提高了植物组织透明的效率,简化了实验步骤。
2)广泛应用:适用于各种植物生物学研究,为科研人员提供了有力的工具。
● HUREL 产品:除了提供肝脏模型外,HUREL还提供一系列体外和3D细胞培养检测服务,包括高内涵筛选、血脑屏障通透性、细胞增殖、癌症相关检测(如抗增殖测定、细胞毒性测定、免疫细胞浸润等)、毒性和安全性评估(如肝、脂肪变性和磷脂沉着症、细胞活力和细胞毒性、毒性、划痕/伤口愈合测定等)。此外,HUREL还提供CLEARED TISSUE 3D成像和分析服务、图像和载玻片分析、数字病理学等高级服务。HUREL 产品具有以下特点:
1)代谢能力卓越: HUREL Micro Liver 的代谢能力部分源于其肝细胞数量增加数倍,因此微量滴定孔内的细胞密度更高。HUREL 能够为 DMPK(药物代谢与药代动力学)研究提供卓越的翻译预测性数据。
2)表型稳定持久:HUREL 微肝具有坚如磐石、持久的表型稳定性,为卓越的代谢能力奠定了基础。将 HUREL平台上生成的数据与悬浮液、单一培养、微图案阵列和 3D 球体培养的原代肝细胞的数据区分开来,进一步证明了其稳定性。
3)同行评审和验证:HUREL 微肝模型已被世界领先的制药公司在数十篇出版物中使用,并且是许多合同研究组织服务不可或缺的一部分。
4)多种肝脏模型物种:包括 HUREL猫、HUREL狗、HUREL人类、HUREL迷你猪等,以及 HUREL灵长类动物、HUREL兔、HUREL大鼠 SD、HUREL大鼠 WH、HUREL 动物板等,以满足不同研究需求。
▍visikol产品列表
<| 品名 | 货号 | Categories | 规格 |
| Visikol® HISTO™ Starter Kit | HSK-1 | HISTO products, Kits, Tissue Clearing | - |
| Visikol® HISTO-1™ | H1-30/H1-100 | HISTO products, Tissue Clearing | 30 ml; 100 ml |
| Visikol® HISTO-2™ | H2-30/H2-100 | HISTO products, Tissue Clearing | 30 ml; 100 ml |
| Visikol® HISTO-1™ and Visikol® HISTO-2™ Combo | HH-10/HH-30/HH-100 | HISTO products, Tissue Clearing | 10 ml; 30 ml; 100 ml |
| Visikol® HISTO-M™ Starter Kit | HMSK-1 | HISTO-M for 3D Cell Culture Models, Kits, Tissue Clearing | - |
| Visikol® HISTO-M™ | HM-30/HM-100 | HISTO-M for 3D Cell Culture Models, Tissue Clearing | 30 ml; 100 ml |
| Visikol® for Plant Biology™ | OV-05/OV-15/OV-30/OV-100 | Tissue Clearing, Visikol for Plant Biology | 5 ml; 15 ml; 30 ml; 100 ml |
| Visikol® HISTO™ Buffer Kit | HSB-BK | Buffers, Kits | - |
| Visikol® HISTO™ Washing Buffer 10X | HSK-WB-70/HSK-WB-200 | Buffers | 70 ml; 200 ml |
| Visikol® HISTO™ Permeabilization Buffer | HSK-PMB-30/HSK-PMB-100 | Buffers | 30 ml; 100 ml |
| Visikol® HISTO™ Penetration Buffer | HSK-PB-30/HSK-PB-100 | Buffers | 30 ml; 100 ml |
| Visikol® HISTO™ Blocking Buffer | HSK-BB-30/HSK-BB-100 | Buffers | 30 ml; 100 ml |
| Visikol® HISTO™ Antibody Buffer | HSK-AB-30/HSK-AB-100 | Buffers | 30 ml; 100 ml |
| Dog Brain Slicer | BSDC-2 | Accessories | 2 mm Coronal |
| Ferret Brain Slicer | BSFC-2/BSFS-2 | Accessories | 2 mm Coronal; 2 mm Sagittal |
| Gerbil Brain Slicer | BSGC-2/BSGS-2 | Accessories | 2 mm Coronal; 2 mm Sagittal |
| Guinea Pig Brain Slicer | BSGPC-2/BSGPS-2 | Accessories | 2 mm Coronal; 2 mm Sagittal |
| Piglet Brain Slicer | BSPC-2 | Accessories | 2mm Slots Piglet |
| Rabbit Brain Slicer | BSRBC-2/BSRBS-2 | Accessories | 2 mm Coronal; 2 mm Sagittal |
| Rat Brain Slicer | 多货号 | Accessories | 多规格 |
| Tissue Slicers | 多货号 | Accessories | 多规格 |
| Two Chambered Dipping Objective Cuvette | DOC-2 | Accessories | - |
| ClearWell™ Silicon Imaging Chambers – Pack of 6 | CW0.75/CW1.75/CW3.5/CW7 | Accessories | 0.75 mm; 1.75 mm; 3.5 mm; 7 mm |
| Mouse Brain Slicer | BSLM-2/BSLM-1/BSLC-1/BSLS-1 | Accessories | 1 mm Coronal/1 mm Sagittal/2 mm Coronal/2 mm Sagittal |

艾美捷科技代理Cell Culture Technologies品牌培养基产品品牌。
Cell Culture Technologies(CCT)是一家瑞士生物技术公司,成立于1992年,创始人为Ferruccio Messi博士;Cell Culture Technologies专注于细胞培养技术领域,拥有深厚的专业知识和技术积累,致力于开发和应用创新的细胞培养解决方案。经典产品:如Hektor G培养基(用于293细胞的日常维护与低温保存)、ChoMaster HTS培养基(用于CHO细胞的低温保存和稳定转染)、InVitrus培养基(用于肾源细胞的常规维护和低温保存)等。这些产品广泛应用于生物制药、细胞疗法、疫苗生产等领域。产品分类包括:
(1)最小培养环境中的细胞培养与冷冻保存:能够在极小的培养环境中对人类和动物细胞系进行培养和冷冻保存,保持细胞的活性和稳定性。
(2)化学定义的无蛋白和无肽培养基:开发了能够在这种培养基中生长的动物细胞生物工艺,为细胞培养提供了更为纯净和可控的环境。
(3)全合成细胞培养基的开发与大规模生产:成功开发出全合成细胞培养基,并实现了大规模生产,满足了生物制药、细胞疗法等领域对高质量细胞培养基的需求。
<<<<<< " data-original="http://biomatik.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Cell Culture Technologies品牌培养基产品"> 艾美捷科技代理Cell Culture Technologies品牌培养基产品

艾美捷科技代理Physitemp品牌。
Physitemp Instruments, Inc. 主要提供温度测量设备、生理监测设备、科研仪器。Physitemp公司的特点包括:(1)设备具有高精度的温度测量功能,确保数据的准确性和可靠性;(2)产品广泛应用于科研、医疗、工业等领域;(3)采用先进的传感技术和数据处理技术,提高设备的性能和功能。产品广泛应用于生物、化学、物理等领域的实验研究;用于体温监测、微循环监测等应用;用于工业设备的温度检测和监控;用于环境温度的监测和记录。
Physitemp主要产品与服务:
(1)温度测量设备:提供多种高精度的温度测量设备,包括热电偶、温度探头、温度记录仪等。
(2)生理监测设备:提供用于生理监测的设备,如体温监测仪、微循环监测仪等。
(3)科研仪器:提供用于科研的仪器,如热像仪、温度校准设备等。
(4)定制解决方案:根据客户需求,提供定制化的温度测量和生理监测解决方案。
<<<< " data-original="http://biomatik.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Physitemp品牌"> 艾美捷科技代理Physitemp品牌
艾美捷科技代理Tatua大拓品牌。
▌公司介绍
大拓位于新西兰畜牧中心地带,是新西兰历史最悠久的乳制品公司,创立于1914年。大拓研发生产专业蛋白胨,用于诊断培养基、发酵培养基、益生菌、生物制药和细胞培养行业,其蛋白胨都符合清真和犹太洁食标准。

更多详情请咨询→

全国免费热线:400-6800-868
直拨专线:+86-027-59626688;18771997407
客服QQ一:17754422825;
客服QQ二:18771149750
▌产品系列
大拓能够提供多样化的蛋白胨组合,以适应全球发酵和益生菌培养基细分市场的一系列应用需求。我司代理的产品类别包括乳糖蛋白胨及植物蛋白胨。
| 乳糖蛋白胨 |
大拓 (Tatua) 提供一系列源自新西兰、无BSE/TSE风险的纯净奶源的乳蛋白胨产品。
● 酪蛋白胨(清真胰蛋白胨):其化学组成、成分和物理特性均经过精心设计,以匹配更传统的胰蛋白酶消化酪蛋白(胰蛋白胨)产品的规格。
● 乳清蛋白胨(乳白蛋白酶解物):能够支持苛养菌的生长,常用于需要特定氨基酸谱的益生菌应用领域。
大拓 (Tatua) 的乳蛋白胨产品组合涵盖广泛的优势,包括:
● 过滤级产品:提供澄清度与热稳定性
● 非过滤级产品:更具成本效益
● 清真 (Halal) 与洁食 (Kosher) 认证
● 多种游离氨基酸谱 (FAA profiles):以支持最佳生长性能
| Product | Protein Source | Filtered | pH | Total Nitrogen | Amino Nitrogen | AN/TN | Ash | Features / Benefits |
| EHCK | Casein | No | 6.6 | 13.80% | 5.50% | 39.90% | 3.50% | ● Cost effective nitrogen source |
| HCP275 | Casein | Yes | 6.9 | 13.60% | 4.30% | 31.80% | 5.50% | ● Halal alternative to tryptone ● Meets pancreatic digest of casein USP criteria |
| HCP321 | Casein | Yes | 6.8 | 13.60% | 5.80% | 42.50% | 4.50% | ● Halal alternative to tryptone ● Good source of free amino acids |
| HCP512 | Casein | Yes | 6.8 | 14.30% | 2.60% | 18.20% | 4.00% | ● Specially designed for use in biopharma fermentations |
| Tatua 2400 | Casein | Yes | 6.9 | 13.40% | 4.40% | 32.90% | 5.80% | ● Supports growth of fastidious bacteria ● Halal alternative to tryptone |
| Tatua 2016 | Whey | Yes | 6.4 | 12.20% | 4.90% | 40.40% | 4.50% | ● Supports growth of fastidious bacteria |
| 植物蛋白胨 |
大拓 (Tatua)将酶解技术和下游加工技术应用于非乳制品蛋白原料,提供无动物成分和/或无过敏原特性的蛋白胨解决方案,作为传统(动物源)蛋白胨的替代品。
● Tatua大豆蛋白胨:是某些诊断培养基配方(如 TSA 和 TSB)的重要组成部分,并且在益生菌发酵应用中表现成熟可靠。
● Tatua豌豆蛋白胨:旨在解决大豆蛋白胨可能引起的大豆过敏原问题而开发,适用于益生菌应用。
<| Product | Protein Source | Filtered | pH | Total Nitrogen | Amino Nitrogen | AN/TN | Ash | Features / Benefits |
| HSP320 | Soy | Yes | 6.9 | 9.20% | 2.50% | 26.90% | 7.10% | ● Good source of free amino acids |
| HSP348 | Soy | No | 7 | 9.10% | 1.70% | 18.60% | 7.80% | ● Cost effective nitrogen and carbohydrate source |
| HSP349 | Soy | Yes | 7 | 9.60% | 1.80% | 19.00% | 7.40% | ● Meets papaic digest of soy USP criteria |
| HSP429 | Soy | Yes | 7.1 | 9.80% | 2.70% | 27.00% | 8.80% | ● Supports growth of fastidious bacteria ● Stable in buffered solutions |
| Tatua 5260 | Pea | Yes | 6.4 | 13.60% | 4.40% | 32.30% | 4.80% | ● Good source of free amino acids ● Dairy-free ● Soy-free |
▌产品优势
大拓微生物营养解决方案具有以下优势:
● 大拓用于生产蛋白胨的乳蛋白原料(酪蛋白和乳清蛋白)都是直接来源于新西兰自有农场的奶源,是唯一一家能够全方位供应乳蛋白原料的蛋白胨生产商
● 新西兰来源的乳蛋白原料符合无BSE/TSE要求
● 植物蛋白为非转基因来源
● 大批量生产(高达8MT)降低单位成本
● FSSC 22000-Q 认证确保满足最高水平的质量要求
● 专业的研发团队能够根据不同培养基的需求提供定制化解决方案
● 出厂保质期为60个月
▌大拓蛋白胨的促生长性能




艾美捷科技代理Nacalai Tesque 品牌。
Nacalai Tesque成立于1980年,Nacalai Tesque专注于精细化学品和研究化学品的研发、生产和销售,特别是生命科学试剂领域。公司通过了ISO 9001、ISO 9002和ISO 14001等国际标准的认证,确保了产品质量和生产环境的可靠性。Nacalai Tesque的产品线广泛,涵盖了生命科学研究的多个方面.
主要包括:
(1)高效液相色谱柱(HPLC柱):该公司生产的高效液相色谱柱不仅基于C18化学,还包括特种化学的色谱柱,能够分离和分析难以用标准C18色谱柱分离的化合物。
(2)细胞培养基及相关产品:提供全面的细胞培养基,包括补充剂、抗生素、小分子、蛋白质等,满足各种细胞培养需求。
(3)蛋白质研究检测试剂盒:支持蛋白质电泳、蛋白质印迹和免疫组织化学等多种应用,为蛋白质研究提供可靠的解决方案。
(4)缓冲液:提供用于分子生物学、细胞生物学、免疫学、神经生物学等领域的缓冲液,确保在各种研究应用中获得高质量的结果。
此外,Nacalai Tesque还生产毒素、抗体、酶等生命科学试剂,以及分离试剂盒、生物试剂和精细化学品等。
<<<<< " data-original="http://biomatik.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Nacalai Tesque品牌"> 艾美捷科技代理Nacalai Tesque品牌地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771149750
传真:18995651644
邮箱:sales@amyjet.com
0.1931